Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody

Sabry M. Attia; Mohammed A. Al-Hamamah; Moureq R. Alotaibi; Abdullah F. Alasmari; Mohamed S.M. Attia; Sheikh F. Ahmad; Mohamed A. Mahmoud; Ahmed Nadeem; Mushtaq A. Ansari; Saleh A. Bakheet

doi:10.1016/j.mrgentox.2023.503635

Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody

Sabry M. Attia^*
, Mohammed A. Al-Hamamah
, Moureq R. Alotaibi
, Abdullah F. Alasmari
, Mohamed S.M. Attia
, Sheikh F. Ahmad
, Mohamed A. Mahmoud
, Ahmed Nadeem
, Mushtaq A. Ansari
, Saleh A. Bakheet

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Rheumatoid arthritis (RA), an autoimmune disorder in which the immune system attacks healthy cells, is associated with elevated risk of lymphoma. Rituximab, a treatment for non-Hodgkin's lymphoma, has been approved as a treatment for RA. We studied the effects of rituximab on chromosomal stability in collagen-induced arthritis DBA/1J animal models. Micronucleus levels were increased in the mouse models, mainly due to chromosome loss, as detected by fluorescence in situ hybridization; rituximab-treated arthritic mice had significantly less micronucleus formation. Serum 8-hydroxydeoxyguanosine, a DNA oxidative stress marker, was increased in the mice models but reduced following rituximab administration.

Original language	English
Article number	503635
Journal	Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Volume	888
DOIs	https://doi.org/10.1016/j.mrgentox.2023.503635
State	Published - 1 May 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2023 Elsevier B.V.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

8-OHdG
Aneugenicity
Anti-CD20
Clastogenicity
Inflammation
Oxidative DNA damage

ASJC Scopus subject areas

Genetics
Health, Toxicology and Mutagenesis

Access to Document

10.1016/j.mrgentox.2023.503635

Cite this

Attia, S. M., Al-Hamamah, M. A., Alotaibi, M. R., Alasmari, A. F., Attia, M. S. M., Ahmad, S. F., Mahmoud, M. A., Nadeem, A., Ansari, M. A., & Bakheet, S. A. (2023). Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 888, Article 503635. https://doi.org/10.1016/j.mrgentox.2023.503635

@article{e7cf49ffbf8945babd16690ae7b1c713,

title = "Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody",

abstract = "Rheumatoid arthritis (RA), an autoimmune disorder in which the immune system attacks healthy cells, is associated with elevated risk of lymphoma. Rituximab, a treatment for non-Hodgkin's lymphoma, has been approved as a treatment for RA. We studied the effects of rituximab on chromosomal stability in collagen-induced arthritis DBA/1J animal models. Micronucleus levels were increased in the mouse models, mainly due to chromosome loss, as detected by fluorescence in situ hybridization; rituximab-treated arthritic mice had significantly less micronucleus formation. Serum 8-hydroxydeoxyguanosine, a DNA oxidative stress marker, was increased in the mice models but reduced following rituximab administration.",

keywords = "8-OHdG, Aneugenicity, Anti-CD20, Clastogenicity, Inflammation, Oxidative DNA damage",

author = "Attia, \{Sabry M.\} and Al-Hamamah, \{Mohammed A.\} and Alotaibi, \{Moureq R.\} and Alasmari, \{Abdullah F.\} and Attia, \{Mohamed S.M.\} and Ahmad, \{Sheikh F.\} and Mahmoud, \{Mohamed A.\} and Ahmed Nadeem and Ansari, \{Mushtaq A.\} and Bakheet, \{Saleh A.\}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = may,

day = "1",

doi = "10.1016/j.mrgentox.2023.503635",

language = "English",

volume = "888",

journal = "Mutation Research - Genetic Toxicology and Environmental Mutagenesis",

issn = "1383-5718",

publisher = "Elsevier B.V.",

}

Attia, SM, Al-Hamamah, MA, Alotaibi, MR, Alasmari, AF, Attia, MSM, Ahmad, SF, Mahmoud, MA, Nadeem, A, Ansari, MA & Bakheet, SA 2023, 'Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody', Mutation Research - Genetic Toxicology and Environmental Mutagenesis, vol. 888, 503635. https://doi.org/10.1016/j.mrgentox.2023.503635

Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody. / Attia, Sabry M.; Al-Hamamah, Mohammed A.; Alotaibi, Moureq R. et al.
In: Mutation Research - Genetic Toxicology and Environmental Mutagenesis, Vol. 888, 503635, 01.05.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody

AU - Attia, Sabry M.

AU - Al-Hamamah, Mohammed A.

AU - Alotaibi, Moureq R.

AU - Alasmari, Abdullah F.

AU - Attia, Mohamed S.M.

AU - Ahmad, Sheikh F.

AU - Mahmoud, Mohamed A.

AU - Nadeem, Ahmed

AU - Ansari, Mushtaq A.

AU - Bakheet, Saleh A.

PY - 2023/5/1

Y1 - 2023/5/1

N2 - Rheumatoid arthritis (RA), an autoimmune disorder in which the immune system attacks healthy cells, is associated with elevated risk of lymphoma. Rituximab, a treatment for non-Hodgkin's lymphoma, has been approved as a treatment for RA. We studied the effects of rituximab on chromosomal stability in collagen-induced arthritis DBA/1J animal models. Micronucleus levels were increased in the mouse models, mainly due to chromosome loss, as detected by fluorescence in situ hybridization; rituximab-treated arthritic mice had significantly less micronucleus formation. Serum 8-hydroxydeoxyguanosine, a DNA oxidative stress marker, was increased in the mice models but reduced following rituximab administration.

AB - Rheumatoid arthritis (RA), an autoimmune disorder in which the immune system attacks healthy cells, is associated with elevated risk of lymphoma. Rituximab, a treatment for non-Hodgkin's lymphoma, has been approved as a treatment for RA. We studied the effects of rituximab on chromosomal stability in collagen-induced arthritis DBA/1J animal models. Micronucleus levels were increased in the mouse models, mainly due to chromosome loss, as detected by fluorescence in situ hybridization; rituximab-treated arthritic mice had significantly less micronucleus formation. Serum 8-hydroxydeoxyguanosine, a DNA oxidative stress marker, was increased in the mice models but reduced following rituximab administration.

KW - 8-OHdG

KW - Aneugenicity

KW - Anti-CD20

KW - Clastogenicity

KW - Inflammation

KW - Oxidative DNA damage

UR - https://www.scopus.com/pages/publications/85151546881

U2 - 10.1016/j.mrgentox.2023.503635

DO - 10.1016/j.mrgentox.2023.503635

M3 - Article

C2 - 37188433

AN - SCOPUS:85151546881

SN - 1383-5718

VL - 888

JO - Mutation Research - Genetic Toxicology and Environmental Mutagenesis

JF - Mutation Research - Genetic Toxicology and Environmental Mutagenesis

M1 - 503635

ER -

Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody

Abstract

Bibliographical note

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this